Latest news
25 items- PRCalyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone-- Dana G. Mead, Jr. brings 30 years of expertise in product strategy, development and commercialization to the Calyxo boardroom, as the company marks its next stage of growth. -- More than 20,000 patients have been treated with the CVAC System, underscoring the increasing adoption of the SURE procedure and its impact in kidney stone care. Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company's CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than
- SECSEC Form 15-12G filed by Inari Medical Inc.15-12G - Inari Medical, Inc. (0001531048) (Filer)
- INSIDERDirector Warner Robert Keith closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERChief Medical Officer Tu Thomas was granted 7,406 shares, closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERDirector Szyman Catherine M. closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERChief Financial Officer Strange Kevin T closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERPrincipal Accounting Officer Silva Karen closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERDirector Root Jonathan D closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERDirector Milder Donald B closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERDirector Mead Dana G Jr. closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERDirector Lucchese Cynthia L closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERPresident and CEO Hykes Andrew was granted 20,393 shares, closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERDirector Hoffman William closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- INSIDERDirector Chambers Rebecca closing all direct ownership in the company (SEC Form 4)4 - Inari Medical, Inc. (0001531048) (Issuer)
- SECSEC Form 25-NSE filed by Inari Medical Inc.25-NSE - Inari Medical, Inc. (0001531048) (Subject)
- SECSEC Form S-8 POS filed by Inari Medical Inc.S-8 POS - Inari Medical, Inc. (0001531048) (Filer)
- SECSEC Form S-8 POS filed by Inari Medical Inc.S-8 POS - Inari Medical, Inc. (0001531048) (Filer)
- SECSEC Form S-8 POS filed by Inari Medical Inc.S-8 POS - Inari Medical, Inc. (0001531048) (Filer)
- SECSEC Form S-8 POS filed by Inari Medical Inc.S-8 POS - Inari Medical, Inc. (0001531048) (Filer)
- SECSEC Form S-8 POS filed by Inari Medical Inc.S-8 POS - Inari Medical, Inc. (0001531048) (Filer)
- SECSEC Form POSASR filed by Inari Medical Inc.POSASR - Inari Medical, Inc. (0001531048) (Filer)
- SECInari Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update8-K - Inari Medical, Inc. (0001531048) (Filer)
- SECAmendment: SEC Form SC TO-T/A filed by Inari Medical Inc.SC TO-T/A - Inari Medical, Inc. (0001531048) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by Inari Medical Inc.SC 14D9/A - Inari Medical, Inc. (0001531048) (Subject)
- PRStryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segmentPortage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk